Introduction
Gestational diabetes (GD) is a syndrome associated with maternal hyperglycaemia and defective insulin signaling in the placenta (Metzger et al., 2007; Colomiere et al., 2009; ADA 2012) . GD have been associated with abnormal fetal development and perinatal complications such as macrosomia, neonatal hypoglicaemia, and neurological disorders (Nold & Georgieff, 2004; Pardo et al., 2012) . The main risk factor to predict the GD development are increased maternal age, overweight before pregnancy, a history of GD in the first pregnancy and history of intolerance abnormal D-glucose (Morisset et al., 2010) . Clinical manifestations of GD have been atribuited to conditions of hyperglicaemia, hyperlipidemia, hyperinsulinemia, and fetal endothelial dysfunction (Nold & segment of umbilical cord and the placenta correspond to vascular beds without innervation (Marzioni et al., 2004) , therefore local regulation of vascular tone results from a balanced combination of the synthesis, release and bioactivity endothelium-derived vasodilators (i.e., nitric oxide (NO), prostanglandins, adenosine) and vasoconstrictors (i.e., endothelin-1, angiotensin II) (Olsson & Pearson, 1990; Becker et al., 2000) . It was reported that arteries and veins in the human placenta from pregnancies with GD have an increase in NO synthesis (Figueroa et al., 2000) . Furthermore, the same result was obtained from primary cultures of human umbilical vein endothelial cells (HUVEC) from pregnant women diagnosed with GD (Sobrevia et al., 1995) . Therefore, vascular disfunction resulting from GD may result from a functional dissociation between NO synthesis and its bioavailability in the human placental circulation (Sobrevia et al., 2011) . Even when endothelial dysfunction is associated with GD, this is referred to as an alteration of NO synthesis and the uptake of cationic aminoacid Larginine (i.e., L-arginine/NO pathway) ( Figure 1 ) and a lack of mechanism behind these effects of GD is still a reality (Pardo et al., 2012) . However, it is accepted that GD is a result of multiple mechanisms of metabolic alteration, including human fetal endothelial sensitivity to vasoactive molecules such as adenosine (Vásquez et 
L-arginine transport in endotelial cells
L-arginine transport in human cells corresponding to different system of amino acids transports, someone of them, it is y + system (high affinity, sodium independent) and sodium dependent (b 0 Grillo et al., 2008) , considered the main L-arginine transport mechanism in different cell types (Tong & Barbul, 2004) . In addition, CAT-1 isoform is the main L-arginine transporter in the placenta (Table 1) (Grillo et al., 2008 ).
Human cationic amino acids transporter 1
Human CAT-1 (hCAT-1) expression is modulated by citokines (i.e., TNFα, TGFβ) ( 
hCAT-1 mediated L-arginine transport regulation
L-Arginine transport via hCAT-1 is regulated by different conditions (Sobrevia & González, 2009; González et al., 2011a) . In HUVEC, hCAT-1 expression increases by tumoral necreosis factor alpha (TNF-α) (Irie et al., 1997; Visigalli et al., 2007) and transforming growth factor beta (TGF-β) (Vásquez et al., 2007) , in the presence of free radicals such as superoxide anion ( 
Regulation of SLC7A1 gene expression
The amino acid cationic transporters family are coding by SLC7A (1-4) gene (Verrey et al., 2004) , where SLC7A1 is coding for hCAT-1 (Hammermann et al., 2001 ). Among the genes coding for CAT-1 in rat, mouse and human there are several common characteristics, i.e., the promoter region lack TATA box, have multiple binding sites for specific protein 1 (Sp1) and have an extensive 3'-untranslated region (3'UTR) which could play roles in the regulation of RNA stability or translation (Aulak et al., 1996 (Aulak et al., , 1999 Fernández et al., 2003; Hatzoglou et al., 2004) . SLC7A1 gene has multiple sites for diferent types of transcription factors such as nuclear factor κB (NF-κB) and Sp1, which is regulated by insulin or inflammatory processes (Sobrevia & González 2009 ). In HUVEC from normal pregnancies it has been described that insulin increased the SLC7A1 transcriptional activity (González et al., 2011a; Guzmán-Gutiérrez et al., 2012a), a mechanism that is Sp1 dependent (between-177 and -105 pb from ATG), However, at present there are not studies in HUVEC from GD ( Figure 2 ). In the proximal promoter of SLC7A1 there are several consensus sequences for transcription factors, including the nuclear factor κB (NF-κB) and specific protein 1 (Sp1) between -115 and -736 pb from the transcriptional start point (ATG). In HUVEC from gestational diabetes (Gestational diabetes) NF-κB and Sp1 could bind to SLC7A1 proximal promoter inducing its transcriptional activity. However, in HUVEC from normal pregnancies (Normal) basal transcriptional activity is commanded mainly by Sp1. The SLC7A1 contains an ATG within the untranslatable region (3'-UTR) and 2 exons (exon -2 and exon -1). This region could be involved in post-transcriptional regulation of hCAT-1 protein. (1) Specific protein 1 (Sp1). The transcriptional factor Sp1 belongs to the super family Sp/Krupellike factor, which is divided into Sp subfamilies, with 8 members (Sp1-Sp8) and KLF subfamily, with 15 members (Solomon et al., 2008) . Then, Sp subfamily is divided into 2 groups Sp1-Sp4 (604-785 amino acids) and Sp5-Sp8 (394-785 amino acids) (Solomon et al., 2008; Wierstra, 2008 Nuclear factor κB. Nuclear factor κB (NF-κB) participates in inflammation being a main element in many diseases whose activation is induced and is protein synthesis independent, requiring post-translational changes to migrate to the nucleus (Grimm et al., 1993) . NF-κB was described as a transcriptional factor activated by several immunological stimules, for example, TNFα and LPS (Crisóstomo et al., 2008; Nakao et al., 2002), or interleukine 1 (IL-1) (Jung et al., 2002) . NF-κB activity is related with inhibitor κB (IκB), which is an inhibitor when is attached to NF-κB (Baldwin, 1996) . Hyperglicaemia increases NF-κB protein abundance in the nucleus in HUVEC, a PI3K/Akt mechanism dependent (Sheu et al., 2005) . Insulin acting in a short time (Visigalli et al., 2007) . In animal models it has been demonstrated that mCAT-2B requires activation of NF-κB in macrophages (Huang et al., 2004) , and that LPS increases mCAT2 levels via NF-κB in these cells (Tsai et al., 2006) . In animal models of GD it has has been demonstrated that NF-κB inhibition leads to an increase in insulin sensitivity in cheeps skeletal muscle (Yan et al., 2010) , and increases GLUT-4 expression in GD rat uterus. However, there is no information regarding the role of NF-κB in human tissues or cells from GD.
Gestational diabetes effect on L-arginine transport in HUVEC
It has been reported that NO levels in amniotic fluid (von Mandach et al., 2003) and NO synthesis in placental vein and artery (Figueroa et al., 2000) are increased in GD. Early studies in HUVEC from GD pregnancies show increased NO synthesis and L-arginine transport (Sobrevia et al., 1995 (Sobrevia et al., , 1997 . These results were associated with an increase in eNOS number of copies for mRNA, protein level and activity (Vásquez et 
Adenosine receptors
Adenosine is a purine nucleoside associated with several biological functions, such as nucleotides synthesis or cellular energetic metabolism (Eltzschig, 2009). Moreover, this nucleoside is a vasodilator in coronary, cerebral, and muscular circulation, in several conditions including hypoxia and exercise (Berne et al., 1983). Extracellular adenosine is a signaling molecule that activates adenosine receptors (ARs). ARs belonging purinergic receptor P1 family, are coupled to G-protein and only four subtypes ARs, A 1 , A 2A , A 2B y A 3 have been described (Fredholm et Table 2 .
Role of adenosine receptors in gestational diabetes
The vasodilatory effect of adenosine, which is endothelial-derived NO-dependent, is mediated by activation of ARs (Sobrevia & . It has been reported that plasma adenosine level in umbilical vein whole blood is higher in GD with respect to normal pregnancies . In addition, umbilical vein blood contained more adenosine compared with umbilical cord arteries in GD, thus suggestsing that an altered placental metabolism of this nucleoside is likely in this syndrome ). These results complement other studies showing increased adenosine concentration in umbilical vein blood from GD compare to normal pregnancies (Maguire et al., 1998) 
Insulin
Insulin is a polypeptide hormone of 51 amino acid residues, synthesized and secreted by β cells in the Langerhans islets of pancreas as an inactive single polypeptide, i.e., preproinsulin, with an N-terminal signal sequence that determines its incorporation to secretory vesicles (Mounier et al., 2006) . The proteolytic elimination of the signal sequence and the formation of three di-sulfur bridges yield the proinsulin. This molecule goes to the Golgi apparatus where it is modified and stored in secretory vesicles (Shepherd, 2004) . The raise of D-glucose in the blood triggers insulin production through conversion of proinsulin to active insulin by proteases that will cut two peptide bonds to form the mature form of insulin in equimolar quantities of C peptide (Shepherd, 2004) . Insulin is the archetypal growth hormone during fetal development, promotes the deposit of carbohydrates, lipids and protein in the tissues and D-glucose uptake. This hexose is the main source of energy in the fetus and its metabolism responds to fetal insulin since the 12 
Role of insulin in gestational diabetes
The studies 'Summary and Recommendations of the Fourth International Workshop-Conference on Gestational Diabetes Mellitus' (Metzger & Coustan, 1998) Initial observations suggested a differential vasodilatory effect of insulin between the macro and microvasculature of the human placenta from fetuses that were appropriate (AGA) or large (LGA) for gestational age in GD (Jo et al., 2009 ). This study shows that insulin-associated vasodilation depends on endothelium-derived NO in umbilical arteries and veins from normal pregnancies or GD, and that insulin did not alter chorionic vessels of normal pregnancies, but generated chorionic vessel relaxation in pregnancies with this syndrome. 
hCAT-1-mediated L-arginine transport regulated by insulin
In primary cultures of HUVEC in euglycemia conditions (i.e., containing 5 mM D-glucose) and in the presence of physiological concentrations of insulin (0.1-1 nM) it has been observed an increase of the maximum velocity of L-arginine transport (V max ), with no significant changes in the apparent K m . This phenomenon was seen in a higher maximum transport capacity (i. (IR-B) . In HUVEC from GD the IR-A/IR-B ratio is 1.6 fold compared with cells from normal pregnanices, an effect due to increased IR-A mRNA expression. However, in hPMEC from GD pregnancies the IR-A mRNA expression was reduced, while IR-B mRNA expression was increased compared with cells from normal pregnancies. Thus, a differential and cell specific involvement of these IR subtypes in GD and perhaps other pathologies of pregnancy, such as pre-eclampsia (Mate et al., 2012) could occur. Insulin, insulin-like growth factor 1 (IGF1) and 2 (IGF2) generate various metabolic and mitogenic effects through activation of receptors associated with tyrosine kinase activity on the surface of the target cells. These hormones have high structural homology. The two receptors may act as ligands for these molecules. At physiological concentrations insulin and IGF1 are attached only to the insulin and IGF receptors, respectively. While, IGF2 receptor binds to IGF1 (IGFR1) and IR-A (Frasca et al., 1999) . The affinity of IGF2 by IR-A is less than that of insulin for this receptor (EC 50 0.9 versus 2.5 nM, respectively), while the binding of IGF1 to IR-A is very high (EC 50 >30 nM). The affinity of IGF2 to IGFR1 is comparable to that of IGF1 (EC 50 0.6 versus 0.2 nM, respectively), where insulin binds weakly to this receptor (EC 50 >30 nM) (Pandini et al., 2002) . Therefore, there may be a differential response to insulin in the fetoplacental vasculature given by preferential activation of one insulin receptor subtype in pregnancies with GD.
Insulin receptors

Insulin effects are modulated by adenosine
Insulin sensitivity is increased in rats supplemented with adenosine in the diet (Ardiansyah et al., 2010) . These data are complemented by similar observations described in diabetic rat adipocytes (Joost & Steinfelder, 1982) , nondiabetic rat skeletal muscle (Vergauwen et al., 1995) , and patients with TIDM who received an infusion of adenosine (Srinivasan et al., 2005) (Table  3) . In other studies, adenosine, agonists and antagonists concentration of adenosine receptors, and insulin used was greater than 100 nM, suggesting for adenosine receptors, that the activation and inhibition of this receptors was complete, and for insulin, involving IR-A, IR-B, and IGF receptors in the system. However, in some studies the concentration of insulin that was used is relatively selective for the receptors of insulin, suggesting the possibility that activation of adenosine receptors increases insulin effect (Webster et AR, but to a lesser degree than the A 1 AR, prevents the development of diabetes in mouse (Németh et al., 2007) . However, a study in C57BL/6J mice suggests that insulin sensitivity decreases by activation of A 2B AR, except in the knockout mouse for this receptor, suggesting that A 2B AR is involved in the phenomenon of insulin resistance (Figler et al., 2011) . This finding opens the possibility that the increase and/or inhibition of the expression or activity of ARs may be associated as a protective mechanism against this syndrome. Recently, we have published that A 2A AR activation in HUVEC from normal pregnancies modulate insulin effect on hCAT-1-mediated L-arginine transport and expression (Guzmán-Gutiérrez et al., 2012a). Interestingly, we saw that in HUVEC from GD insulin reversed GD-increased hCAT-1-mediated L-arginine transport, a mechanism that is dependent on A 1 AR activation (Guzmán-Gutiérrez et al., 2012b). Based on these findings, a possible cross talk between the adenosine receptors and insulin receptors is feasible. This phenomenon could create a potential regulatory mechanism of the biological actions of insulin in the fetoplacental vasculature in GD ( Figure 5 ). 
Concluding remarks
GD associates with endotelial dysfunction in the fetoplacental macro and microcirculation associated with an increase in NO synthesis and hCAT-1 mediated L-arginine transport. Hyperinsulinemia and high plasma adenosine in umbilical blood in GD, suggest the involvement of these molecules in this syndrome. A 2A AR and insulin receptors increase hCAT-1 and eNOS activity and expression in HUVEC from normal, while HUVEC from GD, activation of A 2A AR would be part of mechanism that explain the increase of NO synthesis (i.e., ALANO pathway). In other hands, it has been proposed that insulin acts as a factor that reverses GDincreased NO synthesis and L-arginine transport to values in cells from normal pregnancies. This insulin dual effect can be explained for a differential expression of IR-A and IR-B in normal and GD pregnancies. Insulin effects are dependet on activation of ARs in several cell types, suggesting that adenosine should be act as an isoform insulin receptor activity regulator. Thus, regarding the GD association with increased hCAT-1 expression and activity, there are several not still answered, for example, how is insulin decreasing hCAT-1 activity and expression?, and is adenosine a modulator of the expression and associated signaling of the isoforms of insulin receptors in GD?. Answering these (and other) questions will help us understand insulin mechanisms, opening the possibility to study potential treatment for insulin resistence pathologies including GD. 
